Extended Data Fig. 4: Limited effect of Srebp2 on transcriptional programs of CD8+ T cell differentiation.
From: Metabolic programs of T cell tissue residency empower tumour immunity
a, Srebf2 expression values from the bulk Ultralow-input RNA-seq analysis of shRNAmir control (shCd19) and Srebf2 shRNAmir P14 CD8+ T cells from the spleen, kidney, liver, and SI from day 7 and 14 after LCMV infection. b, Mevalonate-cholesterol synthesis pathway GSVA scores from the bulk Ultralow-input RNA-seq analysis of shRNAmir control (shCd19) and Srebf2 shRNAmir P14 CD8+ T cells from the spleen, kidney, liver, and SI from day 7 and 14 after LCMV infection. c, Unsupervised hierarchically clustered heatmap of mevalonate-cholesterol synthesis pathway gene expression values from the bulk Ultralow-input RNA-seq analysis of shRNAmir control (shCd19) and Srebf2 shRNAmir P14 CD8+ T cells from the spleen, kidney, liver, and SI from day 7 and 14 after LCMV infection. d, Core TRM GSVA scores from the bulk Ultralow-input RNA-seq analysis of shRNAmir control (shCd19) and Srebf2 shRNAmir P14 CD8+ T cells from the spleen, kidney, liver, and SI from day 7 and 14 after LCMV infection. e, Circulating GSVA scores from the bulk Ultralow-input RNA-seq analysis of shRNAmir control (shCd19) and Srebf2 shRNAmir P14 CD8+ T cells from the spleen, kidney, liver, and SI from day 7 and 14 after LCMV infection. f, Volcano plots of differentially expressed genes between shCd19 and shSrebf2 SI P14 CD8+ T cells at days 7 and 14 after LCMV infection, adjusted (adj) p-value. P14 CD8+ T cells from the kidney, liver and SI were gated on the IV− population (a-f). TE were defined as KLRG1highCD127low P14 CD8+ T cells. Data are mean +/− s.e.m.. (a, b, d, and e) from one experiment with n = 2-3 (a-f), where every sample is 1×103 cells pooled from 2~3 mice. Two-sided unpaired t-Test (a, b, d, and e), and Deseq2 DEG testing with Benjamini-Hochberg multiple test correction. *P < 0.05, **P < 0.01, ***P < 0.005.
